Literature DB >> 21893656

Changes in cortical thickness during the course of illness in schizophrenia.

Neeltje E M van Haren1, Hugo G Schnack, Wiepke Cahn, Martijn P van den Heuvel, Claude Lepage, Louis Collins, Alan C Evans, Hilleke E Hulshoff Pol, René S Kahn.   

Abstract

CONTEXT: Whether cortical thickness changes in schizophrenia over time are more pronounced relative to the changes that can be attributed to normal aging has not been studied.
OBJECTIVE: To compare patients with schizophrenia and healthy control participants on cortical thickness change.
DESIGN: A 5-year longitudinal study comparing schizophrenic patients and healthy controls using 2 magnetic resonance images of the brain.
SETTING: Patients were recruited from the Department of Psychiatry at the University Medical Centre Utrecht and from other psychiatric hospitals in the Netherlands. Healthy controls were recruited via advertisement in newspapers and notice boards. PARTICIPANTS: Ninety-six schizophrenic patients and 113 healthy controls aged 16 to 56 years. MAIN OUTCOME MEASURES: Cortical thickness and change in cortical thickness on a vertex-by-vertex basis across the cortical mantle, measures of functional and symptomatic outcome, and cumulative intake of antipsychotics during the scan interval.
RESULTS: At baseline, the schizophrenic patients had thinner left orbitofrontal and right parahippocampal and superior temporal cortices and a thicker superior parietal lobule and occipital pole compared with the controls. Mean cortical thickness did not differ between the groups. Over time, excessive cortical thinning was found in widespread areas on the cortical mantle, most pronounced bilaterally in the temporal cortex and in the left frontal area. Poor outcome in patients was associated with more pronounced cortical thinning. Higher cumulative intake of typical antipsychotics during the scan interval was associated with more pronounced cortical thinning, whereas higher cumulative intake of atypical antipsychotic medication was associated with less pronounced cortical thinning.
CONCLUSIONS: In schizophrenia, the cortex shows excessive thinning over time in widespread areas of the brain, most pronounced in the frontal and temporal areas, and progresses across the entire course of the illness. The excessive thinning of the cortex appears related to outcome and medication intake.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21893656     DOI: 10.1001/archgenpsychiatry.2011.88

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  110 in total

Review 1.  Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?

Authors:  Nenad Vasic; Bernhard J Connemann; Robert C Wolf; Hayrettin Tumani; Johannes Brettschneider
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-12-16       Impact factor: 5.270

2.  Longitudinal progression of frontal and temporal lobe changes in schizophrenia.

Authors:  Derin J Cobia; Matthew J Smith; Lei Wang; John G Csernansky
Journal:  Schizophr Res       Date:  2012-05-29       Impact factor: 4.939

Review 3.  Glutamate-mediated excitotoxicity in schizophrenia: a review.

Authors:  Eric Plitman; Shinichiro Nakajima; Camilo de la Fuente-Sandoval; Philip Gerretsen; M Mallar Chakravarty; Jane Kobylianskii; Jun Ku Chung; Fernando Caravaggio; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Eur Neuropsychopharmacol       Date:  2014-08-01       Impact factor: 4.600

4.  Evaluation of Myo-Inositol as a Potential Biomarker for Depression in Schizophrenia.

Authors:  Joshua Chiappelli; Laura M Rowland; S Andrea Wijtenburg; Florian Muellerklein; Malle Tagamets; Robert P McMahon; Frank Gaston; Peter Kochunov; L Elliot Hong
Journal:  Neuropsychopharmacology       Date:  2015-02-27       Impact factor: 7.853

5.  Morphometry of superior temporal gyrus and planum temporale in schizophrenia and psychotic bipolar disorder.

Authors:  J Tilak Ratnanather; Clare B Poynton; Dominic V Pisano; Britni Crocker; Elizabeth Postell; Shannon Cebron; Elvan Ceyhan; Nancy A Honeycutt; Pamela B Mahon; Patrick E Barta
Journal:  Schizophr Res       Date:  2013-09-06       Impact factor: 4.939

6.  Association of a risk allele of ANK3 with cognitive performance and cortical thickness in patients with first-episode psychosis.

Authors:  Clifford Cassidy; Lisa Buchy; Michael Bodnar; Jennifer Dell'elce; Zia Choudhry; Ferid Fathalli; Sarojini Sengupta; Rebecca Fox; Ashok Malla; Martin Lepage; Srividya Iyer; Ridha Joober
Journal:  J Psychiatry Neurosci       Date:  2014-01       Impact factor: 6.186

Review 7.  [Frontal brain volume reduction due to antipsychotic drugs?].

Authors:  V Aderhold; S Weinmann; C Hägele; A Heinz
Journal:  Nervenarzt       Date:  2015-03       Impact factor: 1.214

8.  Linking Cortical and Connectional Pathology in Schizophrenia.

Authors:  Maria Angelique Di Biase; Vanessa L Cropley; Luca Cocchi; Alexander Fornito; Fernando Calamante; Eleni P Ganella; Christos Pantelis; Andrew Zalesky
Journal:  Schizophr Bull       Date:  2019-06-18       Impact factor: 9.306

9.  Neuropathological changes in the nucleus basalis in schizophrenia.

Authors:  M R Williams; R Marsh; C D Macdonald; J Jain; R K B Pearce; S R Hirsch; O Ansorge; S M Gentleman; M Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-12-11       Impact factor: 5.270

Review 10.  Neurocognitive, Neuroprotective, and Cardiometabolic Effects of Raloxifene: Potential for Improving Therapeutic Outcomes in Schizophrenia.

Authors:  Mohammad M Khan
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.